鍏充簬娆х媱娌�<\/b><\/p> \n
*娆х媱娌冧负鍩虹鐨勫厤鐤崟鑽不鐤楀強鍏嶇柅鑱斿悎娌荤枟鏂规<\/i><\/p> \n
鍏充簬鐧炬椂缇庢柦璐靛疂涓浗<\/u><\/b><\/p> \n
鐧炬椂缇庢柦璐靛疂鏄竴瀹朵互"鐮斿彂骞舵彁渚涘垱鏂拌嵂鐗╋紝甯姪鎮h€呮垬鑳滀弗閲嶇柧鐥�"涓轰娇鍛界殑鍏ㄧ悆棰嗗厛鐨勭敓鐗╁埗鑽叕鍙革紝濮嬬粓璺佃"寮曢绉戝锛屾敼鍙樻偅鑰呯敓鍛�"鐨勪紒涓氭効鏅€傚湪涓浗锛岀櫨鏃剁編鏂借吹瀹濊嚧鍔涗簬鎴愪负"鏍规涓浗銆佹簮浜庝腑鍥�"鐨勫垱鏂伴瀵艰€咃紝涓撴敞浜庡姞閫熷紩杩涘叕鍙稿湪鑲跨槫瀛︺€佽娑插鍜屽厤鐤绛夋牳蹇冪柧鐥呴鍩熺殑鍒涙柊鑽墿锛屾棭鏃ユ儬鍙婁腑鍥芥偅鑰呫€�<\/p> \n
鏂板熀涓庢湵璇哄尰鐤楁槸鐧炬椂缇庢柦璐靛疂鍏徃鐨勫叏璧勫瓙鍏徃銆傚湪缇庡浗浠ュ鐨勯儴鍒嗗競鍦猴紝閴翠簬褰撳湴娉曞緥锛屾柊鍩哄拰鏈辫鍖荤枟鍒嗗埆琚О涔嬩负鏂板熀 -- 涓€瀹剁櫨鏃剁編鏂借吹瀹濈殑鍏徃鍜屾湵璇哄尰鐤� -- 涓€瀹剁櫨鏃剁編鏂借吹瀹濈殑鍏徃銆�<\/p> \n
濡傞渶浜嗚В鏇村淇℃伅锛岃娴忚鐧炬椂缇庢柦璐靛疂涓浗瀹樻柟缃戠珯www.bms.com.cn<\/a>鎴栧叧娉ㄧ櫨鏃剁編鏂借吹瀹濅腑鍥藉畼鏂瑰井淇″叕浼楀彿鍙婂畼鏂硅棰戝彿銆�<\/p> \n
[1] Forde PM et al, Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer, The New England Journal of Medicine 2022; 386:1973-1985.
[2] Global Cancer Observatory: Cancer Today. Lyon, France<\/span>: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.fr\/today<\/a>.
[3] 涓浗涓村簥鑲跨槫瀛︿細鎸囧崡宸ヤ綔濮斿憳浼氾紝銆婁腑鍥戒复搴婅偪鐦ゅ浼氾紙CSCO锛夊厤鐤鏌ョ偣鎶戝埗鍓備复搴婂簲鐢ㄦ寚鍗�2022銆�.
[4] National Comprehensive Cancer Network 2022, Non-Small Cell Lung Cancer, Version 5.2022, Sep. 26, 2022<\/span>.<\/p>"];
$("#dvExtra").html(content_array[0]);})();